Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage ...

Our drive to greater drug pricing transparency through innovation has never been more needed,” Ed DeVaney says.

We recently compiled a list of the 10 Best Performing S&P 500 Stocks So Far in 2025. In this article, we are going to take a ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

Principal Securities Inc. grew its holdings in shares of CVS Health Co. (NYSE:CVS – Free Report) by 3.2% during the fourth ...

Argus raised the firm’s price target on CVS Health (CVS) to $77 from $68 and keeps a Buy rating on the shares. Despite an uneven performance ...

CVS Health® (NYSE: CVS) named Ed DeVaney president of the company's CVS Caremark pharmacy benefit management business. He was named interim president in December 2024. DeVaney will report to Prem Shah ...

HARTFORD-- This week, the CEO of CVS Health expressed confidence that the company would turn around its embattled health-insurance business, the Hartford- based Aetna. "People used to refer to Aetna ...

CVS Health (NYSE:CVS – Free Report) had its price target lifted by JPMorgan Chase & Co. from $80.00 to $81.00 in a report ...

The appointment marks the latest in a spate of leadership changes at CVS as the company’s insurance segment struggles to ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

The Prescription Drug Affordability Act would aim to stop pharmacy benefit managers, or PBMs, from “exploiting loopholes” to ...